A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINATION WITH MMF (CELLCEPT) AND STEROIDS IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION

A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINATION WITH MMF (CELLCEPT®) AND STEROIDS IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION

Registry ID

EUCTR2004-000304-41

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

FUJISAWA

Start date

2004-07-27

Last update

2026-08-16

Conditions

• Kidney transplantation
• Patients with end stage kidney disease who will undergo renal transplantation

Summary

Kidney transplantation

Locations

• , , Czechia
• , , Sweden
• , , Hungary
• , , Finland
• , , Austria
• , , Italy

Related clinical trials

• Screening for subclinical antibody mediated rejection and efficacy of belatacept in the context of de novo donor specific antibody after kidney transplantation / BEL-AMR

View on source registry